Chemo/Immunotherapy Data Increasingly Compelling with Additional Follow-Up (BMIC-009)

25/09/2017 7 min
Chemo/Immunotherapy Data Increasingly Compelling with Additional Follow-Up (BMIC-009)

Listen "Chemo/Immunotherapy Data Increasingly Compelling with Additional Follow-Up (BMIC-009)"

Episode Synopsis

Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer follow-up of the KEYNOTE-021g trial.

More episodes of the podcast The Beacon (Audio)